Meropenem Steriscience

Meropenem, the active ingredient in Meropenem Steriscience, is a carbapenem presented as an injectable solution for intravenous infusion use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, meningitis, and sepsis in hospitalized patients.

GNH USA supplies Meropenem Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by Gram‑negative and Gram‑positive bacteria. - Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication. - Complicated urinary tract infections: provides rapid bacterial clearance and symptom resolution. - Hospital‑acquired pneumonia: improves survival and resolves pulmonary infection. - Ventilator‑associated pneumonia: targets resistant pathogens and supports recovery. - Meningitis: penetrates cerebrospinal fluid to eradicate causative organisms. - Severe sepsis and septic shock: contributes to hemodynamic stabilization and infection control.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Infusion site phlebitis: pain or redness at the IV site. - Elevated liver enzymes: transient increase in ALT/AST. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity. - Clostridioides difficile‑associated diarrhea: severe colitis. - Neutropenia: marked reduction in neutrophil count. - Renal impairment: acute kidney injury. - Severe hypersensitivity reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function: adjust dose in patients with impaired clearance. - Hypersensitivity: avoid in individuals with known carbapenem allergy. - Pregnancy: use only if benefits outweigh potential risks, as safety data are limited. - Seizure risk: monitor neurologic status, especially in CNS‑compromised patients. - Concomitant valproic acid: anticipate reduced seizure control. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several medicines; clinical judgment is required. Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum concentrations, risking seizure breakthrough. - Other carbapenems: concurrent use may increase toxicity without added benefit. - Aminoglycosides: combined nephrotoxic potential. Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - NSAIDs: may exacerbate renal impairment. - Warfarin: observe INR for possible alteration. - Oral contraceptives: reduced efficacy, advise backup contraception.